Evotec SE ADR (EVO)vsTeva Pharma Industries Ltd ADR (TEVA)
EVO
Evotec SE ADR
$1.32
-8.97%
HEALTHCARE · Cap: $600.61M
TEVA
Teva Pharma Industries Ltd ADR
$39.23
+1.79%
HEALTHCARE · Cap: $50.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 2299% more annual revenue ($17.23B vs $718.32M). TEVA leads profitability with a 2.9% profit margin vs -25.2%. TEVA appears more attractively valued with a PEG of 1.04. TEVA earns a higher WallStSmart Score of 42/100 (D).
EVO
Hold42
out of 100
Grade: D
TEVA
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.5%
Fair Value
$33.26
Current Price
$1.32
$31.94 discount
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Strong operational efficiency at 27.4%
Areas to Watch
0.6% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -28.6% — below average capital efficiency
ROE of 6.3% — below average capital efficiency
2.9% margin — thin
Premium valuation, high expectations priced in
Revenue declined 1.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : EVO
The strongest argument for EVO centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.
Bull Case : TEVA
The strongest argument for TEVA centers on Market Cap, Operating Margin. PEG of 1.04 suggests the stock is reasonably priced for its growth.
Bear Case : EVO
The primary concerns for EVO are Revenue Growth, EPS Growth, Market Cap.
Bear Case : TEVA
The primary concerns for TEVA are Return on Equity, Profit Margin, P/E Ratio. A P/E of 99.9x leaves little room for execution misses. Debt-to-equity of 2.13 is elevated, increasing financial risk.
Key Dynamics to Monitor
EVO profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.
EVO carries more volatility with a beta of 1.31 — expect wider price swings.
EVO is growing revenue faster at 0.6% — sustainability is the question.
TEVA generates stronger free cash flow (121M), providing more financial flexibility.
Bottom Line
EVO scores higher overall (42/100 vs 42/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evotec SE ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evotec SE is a prominent global biotechnology company headquartered in Hamburg, Germany, specializing in delivering comprehensive drug discovery and development solutions to the pharmaceutical and biotech industries. The firm is distinguished by its collaborative strategy, forming partnerships with leading pharmaceutical entities and prestigious academic institutions to accelerate the progress of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline, Evotec is strategically positioned to leverage new opportunities within the biopharmaceutical sector, reaffirming its essential contribution to healthcare innovation and improved patient outcomes.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?